Of notable interest is the synergistic potential observed when combining anti-PD-L1 agents with therapies aimed at mitigating myeloid-derived suppressor cell activity or inhibiting poly ADP-ribose polymerase, especially in cases of castration-resistant prostate cancer [18,19]. Here, CD274 is linked to prostate carcinoma.